<DOC>
	<DOCNO>NCT00001034</DOCNO>
	<brief_summary>To evaluate safety efficacy oral ganciclovir prophylaxis cytomegalovirus ( CMV ) retinal gastrointestinal mucosal disease HIV-infected patient severe immunosuppression . The recent treatment CMV disease ganciclovir foscarnet . Until recently , drug require intravenous administration . An oral form ganciclovir , show effective therapy CMV , would suitable method administration prophylaxis .</brief_summary>
	<brief_title>The Safety Effectiveness Ganciclovir Prevention Cytomegalovirus ( CMV ) Eyes Disease Stomach Intestines Patients With HIV</brief_title>
	<detailed_description>The recent treatment CMV disease ganciclovir foscarnet . Until recently , drug require intravenous administration . An oral form ganciclovir , show effective therapy CMV , would suitable method administration prophylaxis . Patients randomize 2:1 ratio receive either oral ganciclovir placebo minimum 12 month . PER AMENDMENT 9/19/94 : Patients reach study endpoint may choose continue blind prophylaxis discontinue blind prophylaxis begin open-label ganciclovir . PER AMENDMENT 5/2/95 : After common closing date ( 6/3/95 ) patient meet CMV end point experience serious toxicity require permanent discontinuation active oral ganciclovir eligible receive open-label oral ganciclovir open-label extension phase study 023 8/31/95 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Gastrointestinal Diseases</mesh_term>
	<mesh_term>Digestive System Diseases</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiretroviral therapy . AntiPCP prophylaxis . Maintenance prophylaxis therapy opportunistic infection besides CMV . Patients must : Working diagnosis HIV infection . CD4 count &lt; = 100 cells/mm3 . Positive CMV serology ( IgG ) CMV culture , absence active disease , document time prior study entry . Reasonably good health . Life expectancy least 6 month . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Acute lifethreatening illness . Active lymphoma . Hypersensitivity acyclovir . Lack willingness ability , opinion clinician , comply protocol requirement . Concurrent Medication : Excluded : Vidarabine . Amantadine hydrochloride ( Symmetrel ) . CMV hyperimmune globulin/intravenous immune globulin . Cytarabine . Fiacitabine ( FIAC ) fialuridine ( FIAU ) . Foscarnet . Intravenous ganciclovir . HPMPC . Idoxuridine . Intravenous acyclovir . Oral acyclovir &gt; 1 g/day . Other drug potential antiCMV activity . Prior Medication : Excluded within 60 day prior study entry : Foscarnet . Excluded within 2 week prior study entry : Vidarabine . Amantadine hydrochloride ( Symmetrel ) . CMV hyperimmune globulin/intravenous immune globulin . Cytarabine . Fiacitabine ( FIAC ) fialuridine ( FIAU ) . Ganciclovir . HPMPC . Idoxuridine . Intravenous acyclovir . Oral acyclovir &gt; 1 g/day . Other drug potential antiCMV activity .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Gastrointestinal System</keyword>
</DOC>